Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Page Options
E-Mail This Search
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
or
LiveHelp online chat
Quick Links
Help Using the NCI Clinical Trials Search Form
Educational Materials About Clinical Trials
About NCI's Cancer Clinical Trials Registry
Dictionary of Cancer Terms
NCI Drug Dictionary
View Content for:
Patients
Health Professionals
Display:
Title
Description with:
Locations
Eligibility
Full Trial Description
Custom
Results 1-10 of 10 for your search:
Drug:
imiquimod
Find trials that include:
Any drugs shown
Trial Status:
Closed
Hide Search Criteria
Show Search Criteria
Help with Results
Select All on Page
Sort by:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Show
10
25
50
100
200
Results per Page
1.
Intron-A/Aldara Combination Therapy for Basal Cell Carcinoma (BCC)
Phase:
Phase IV
Type:
Treatment
Status:
Closed
Age:
Not specified
Sponsor:
Other
Protocol IDs:
HSC-MS-06-0478
, OSP-24412, NCT00581425
2.
Topical Imiquimod for Bowen's Disease of the Head and Neck
Phase:
Phase III, Phase II
Type:
Prevention, Treatment
Status:
Enrolling by invitation
Age:
18 and over
Sponsor:
Other
Protocol IDs:
C.2005.087
, NCT00384124
3.
Phase III Randomized Study of Topical Imiquimod Versus Excisional Surgery in Patients With Nodular or Superficial Basal Cell Skin Cancer
Phase:
Phase III
Type:
Treatment
Status:
Closed
Age:
Any age
Sponsor:
Other
Protocol IDs:
CRUK-LON-SINS-C7484/A2869
, EU-20205, NCT00066872
4.
Phase II Randomized Chemoprevention Study of Topical Imiquimod Preceding Local Ablative or Excisional Therapy in Patients With Recurrent or High-Grade Cervical Intraepithelial Neoplasia
Phase:
Phase II
Type:
Prevention
Status:
Completed
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
NCCTG-989251
, NCI-P02-0208, NCT00031759
5.
Safety and Immunogenicity of CYT004-MelQbG10 Vaccine With and Without Adjuvant in Advanced Stage Melanoma Patients
Phase:
Phase II
Type:
Treatment
Status:
Closed
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
CYT004-MelQbG10 04
, NCT00651703
6.
Phase I Randomized Study of Imiquimod 5% Cream in Patients With Basal Cell Skin Cancer
Phase:
Phase I
Type:
Treatment
Status:
Closed
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
NCI-02-CC-0289
, 3M-1454-IMIQ, NCT00079300
7.
Phase I Randomized Study of Adjuvant Transdermal Vaccine Therapy Comprising Multi-Epitope Melanoma Peptides, Tetanus Toxoid Helper Peptide, and Sargramostim (GM-CSF) in Combination With Either Montanide ISA-51 or Dimethyl Sulfoxide With or Without Imiquimod in Patients With Resected Stage II-IV Melanoma
Phase:
Phase I
Type:
Treatment
Status:
Closed
Age:
12 and over
Sponsor:
NCI
Protocol IDs:
UVACC-MEL-45
, UVACC-HIC-11490, UVACC-34204, NCT00118313
8.
NY-ESO-1 Protein Vaccine With Imiquimod in Melanoma (Adjuvant Setting)
Phase:
Phase I
Type:
Treatment
Status:
Completed
Age:
18 and over
Sponsor:
Other
Protocol IDs:
NYU 04-53, LUD2004-006
, NCT00142454
9.
Phase I Pilot Study of In Situ Photoimmunotherapy Comprising Imiquimod and Infrared Laser Therapy With or Without Indocyanine Green in Patients With Stage III or IV Melanoma and Cutaneous Metastases
Phase:
Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Closed
Age:
18 to 100
Sponsor:
Other
Protocol IDs:
OU-12576
, 12576, OU-ISPI, NCT00453050
10.
Pilot Study of Regulatory T-Cell Inhibition With Daclizumab During Antitumor Immunotherapy Targeted Against Cytomegalovirus in Patients With Newly Diagnosed Glioblastoma Multiforme and Therapeutic Temozolomide-Induced Lymphopenia
Phase:
No phase specified
Type:
Diagnostic, Treatment
Status:
Closed
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
DUMC-PRO00000581
, Pro00000581, SPORE Project 3, NCT00626483
Select All on Page
Help with Results
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute